OBiO Tech's net loss for the fiscal year 2024 is 325 million yuan, with losses widening

OBiO Tech released its 2024 annual performance report, with total operating revenue of 247 million yuan, a year-on-year increase of 20.60%. However, the net loss attributable to the parent company's owners expanded to 325 million yuan, with a net loss of 336 million yuan after deducting non-recurring gains and losses, resulting in a basic loss per share of 0.502 yuan. The company actively responds to challenges in the biopharmaceutical field, maintains stable growth in its CRO business, and promotes the expansion of its CDMO business

According to the Zhitong Finance APP, OBiO Tech (688238.SH) released its performance report for the year 2024. The total operating revenue for 2024 is 247 million yuan, a year-on-year increase of 20.60%; the net loss attributable to the parent company's owners is 325 million yuan, with losses widening; the net loss attributable to the parent company's owners after deducting non-recurring gains and losses is 336 million yuan, with losses widening; the basic loss per share is 0.502 yuan.

During the reporting period, the company actively faced various opportunities and challenges in the domestic biopharmaceutical field, adhering to the "customer first" business philosophy and continuing to effectively reserve customer resources. On one hand, it continuously seeks new breakthroughs in business, maintaining stable growth in the cell and gene therapy CRO business; on the other hand, it strives to promote the continuous release of capacity advantages in the Lingang large-scale industrial base, supporting the advancement of domestic cell and gene therapy drug R&D enterprise projects, and making progress in expanding the CDMO business area, order scale, and project delivery. The company's operating revenue achieved certain growth during the reporting period